Navigation Links
Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting
Date:4/9/2008

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that preclinical data evaluating the mechanism of action and therapeutic potential of NU206 (R-spondin1) for chemotherapy or radiation-induced oral mucositis, and preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in mouse models of colorectal cancer, will be presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA, April 12-16, 2008.

The presentation details are as follows:

Date/Time: Sunday, April 13, 2008, 1:00 - 5:00 p.m. PT

Poster Title (#1495): R-spondin1 protects mice from chemotherapy or radiation-induced oral mucositis by activating canonical Wnt/beta-catenin pathway

Location: Poster Board #2, Section 32, Exhibit Hall B-F, San Diego Convention Center

Date/Time: Wednesday, April 16, 2008, 8:00 a.m. - 12:00 p.m. PT

Poster Title (#5698): rNAPc2 inhibits colorectal cancer in mouse models through tissue factor

Location: Poster Board #11, Section 31, Exhibit Hall B-F, San Diego Convention Center

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's annual report on Form 10-K for the year ended December 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 , ... ... is needed and will ultimately do significant harm to people with all chronic ... , "While it leaves in place the Affordable Care Act (ACA) requirement ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Act (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care ... Senate bill would make significant cuts to Medicaid, a public health insurance program ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of ... deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently ... , Bowman brings an intimacy with the issues and challenges veterans face with the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and ... to the JFK Virgin Atlantic lounge. , Bensko is no stranger to the ... ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the ... at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is ... who owns three other locations in the Topeka and Bonner Springs, Kan. area. ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a medical ... of intravenous (IV) therapy, is pleased to announce it ... of Nonsurgical Hospital Supplies and Equipment at the 2017 ... for the medtech industry. The award was presented by ... K. Javits Center in New York ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/8/2017)... --  Responding to Heath Ledger,s father,s recent call ... Chris Cornell in May, the mental health watchdog ... online psychiatric drug side effects search engine ... drug risks. The father of the late ... overdose, has called for tighter rules on prescription drugs. Speaking ...
Breaking Medicine Technology: